povorcitinib   Click here for help

GtoPdb Ligand ID: 11881

Synonyms: compound 7 [US20210238168A1] | Povofortay®
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. It is one of the examples claimed in Incyte's JAK inhibitor patent US20210238168A1 [1], which indicates selectivity for JAK1. At that time information on Incyte's pipeline page suggested that povorcitinib may be the INN for their oral JAK1 inhibitor clinical lead INCB54707, and this INN-to-code name was formally confirmed in 2026 [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 102.63
Molecular weight 507.18
XLogP 4.79
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES N#CCC1(CN(C1)c1cc(F)c(cc1F)C(=O)N[C@H](C(F)(F)F)C)n1ncc(c1)c1c(C)n[nH]c1C
Isomeric SMILES C(#N)CC1(CN(C1)c1cc(c(C(=O)N[C@H](C(F)(F)F)C)cc1F)F)n1ncc(c1)c1c(n[nH]c1C)C
InChI InChI=1S/C23H22F5N7O/c1-12-20(13(2)33-32-12)15-8-30-35(9-15)22(4-5-29)10-34(11-22)19-7-17(24)16(6-18(19)25)21(36)31-14(3)23(26,27)28/h6-9,14H,4,10-11H2,1-3H3,(H,31,36)(H,32,33)/t14-/m0/s1
InChI Key MSGYSFWCPOBHEV-AWEZNQCLSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Povorcitinib is a clinical candidate for the treatment of hidradenitis suppurativa, chronic spontaneous urticaria and other inflammatory conditions
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05936567 Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Phase 2 Interventional Incyte Corporation
NCT05620823 A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa Phase 3 Interventional Incyte Corporation The STOP-HS1 study 2
NCT05620836 A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 3 Interventional Incyte Corporation The STOP-HS2 study 2